BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 37475115)

  • 1. Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational study.
    Cohn H; Bloom N; Cai GY; Clark JJ; Tarke A; Bermúdez-González MC; Altman DR; Lugo LA; Lobo FP; Marquez S; ; Chen JQ; Ren W; Qin L; Yates JL; Hunt DT; Lee WT; Crotty S; Krammer F; Grifoni A; Sette A; Simon V; Coelho CH
    Lancet Infect Dis; 2023 Nov; 23(11):1302-1312. PubMed ID: 37475115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mpox vaccine and infection-driven human immune signatures.
    Cohn H; Bloom N; Cai G; Clark J; Tarke A; Bermúdez-González MC; Altman D; Lugo LA; Lobo FP; Marquez S; ; Chen JQ; Ren W; Qin L; Crotty S; Krammer F; Grifoni A; Sette A; Simon V; Coelho CH
    medRxiv; 2023 Mar; ():. PubMed ID: 36945651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of JYNNEOS Vaccine Against Diagnosed Mpox Infection - New York, 2022.
    Rosenberg ES; Dorabawila V; Hart-Malloy R; Anderson BJ; Miranda W; O'Donnell T; Gonzalez CJ; Abrego M; DelBarba C; Tice CJ; McGarry C; Mitchell EC; Boulais M; Backenson B; Kharfen M; McDonald J; Bauer UE
    MMWR Morb Mortal Wkly Rep; 2023 May; 72(20):559-563. PubMed ID: 37339074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the immunogenicity and protective efficacy of ACAM2000, MVA, and vectored subunit vaccines for Mpox in rhesus macaques.
    Jacob-Dolan C; Ty D; Hope D; McMahan K; Liu J; Powers OC; Cotter CA; Sciacca M; Wu C; Borducchi E; Bouffard E; Richter H; Velasco J; Teow E; Boursiquot M; Cook A; Feliciano K; Yalley-Ogunro J; Seaman MS; Pessiant L; Lewis MG; Andersen H; Moss B; Barouch DH
    Sci Transl Med; 2024 Mar; 16(740):eadl4317. PubMed ID: 38536937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara-Bavaria Nordic vaccine against mpox in children: a national outbreak response.
    Ladhani SN; Dowell AC; Jones S; Hicks B; Rowe C; Begum J; Wailblinger D; Wright J; Owens S; Pickering A; Shilltoe B; McMaster P; Whittaker E; Zuo J; Powell A; Amirthalingam G; Mandal S; Lopez-Bernal J; Ramsay ME; Kissane N; Bell M; Watson H; Ho D; Hallis B; Otter A; Moss P; Cohen J
    Lancet Infect Dis; 2023 Sep; 23(9):1042-1050. PubMed ID: 37336224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview on mRNA-based vaccines to prevent monkeypox infection.
    Natami M; Gorgzadeh A; Gholipour A; Fatemi SN; Firouzeh N; Zokaei M; Mohammed Ali SH; Kheradjoo H; Sedighi S; Gholizadeh O; Kalavi S
    J Nanobiotechnology; 2024 Mar; 22(1):86. PubMed ID: 38429829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serological responses to the MVA-based JYNNEOS monkeypox vaccine in a cohort of participants from the Democratic Republic of Congo.
    Priyamvada L; Carson WC; Ortega E; Navarra T; Tran S; Smith TG; Pukuta E; Muyamuna E; Kabamba J; Nguete BU; Likafi T; Kokola G; Lushima RS; Tamfum JM; Okitolonda EW; Kaba DK; Monroe BP; McCollum AM; Petersen BW; Satheshkumar PS; Townsend MB
    Vaccine; 2022 Nov; 40(50):7321-7327. PubMed ID: 36344361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study - United States, August 19, 2022-March 31, 2023.
    Dalton AF; Diallo AO; Chard AN; Moulia DL; Deputy NP; Fothergill A; Kracalik I; Wegner CW; Markus TM; Pathela P; Still WL; Hawkins S; Mangla AT; Ravi N; Licherdell E; Britton A; Lynfield R; Sutton M; Hansen AP; Betancourt GS; Rowlands JV; Chai SJ; Fisher R; Danza P; Farley M; Zipprich J; Prahl G; Wendel KA; Niccolai L; Castilho JL; Payne DC; Cohn AC; Feldstein LR; ;
    MMWR Morb Mortal Wkly Rep; 2023 May; 72(20):553-558. PubMed ID: 37200229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United States.
    Deputy NP; Deckert J; Chard AN; Sandberg N; Moulia DL; Barkley E; Dalton AF; Sweet C; Cohn AC; Little DR; Cohen AL; Sandmann D; Payne DC; Gerhart JL; Feldstein LR
    N Engl J Med; 2023 Jun; 388(26):2434-2443. PubMed ID: 37199451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons - 43 U.S. Jurisdictions, July 31-October 1, 2022.
    Payne AB; Ray LC; Cole MM; Canning M; Houck K; Shah HJ; Farrar JL; Lewis NM; Fothergill A; White EB; Feldstein LR; Roper LE; Lee F; Kriss JL; Sims E; Spicknall IH; Nakazawa Y; Gundlapalli AV; Shimabukuro T; Cohen AL; Honein MA; Mermin J; Payne DC
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(49):1560-1564. PubMed ID: 36480479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receipt of First and Second Doses of JYNNEOS Vaccine for Prevention of Monkeypox - United States, May 22-October 10, 2022.
    Kriss JL; Boersma PM; Martin E; Reed K; Adjemian J; Smith N; Carter RJ; Tan KR; Srinivasan A; McGarvey S; McGehee J; Henderson D; Aleshire N; Gundlapalli AV
    MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(43):1374-1378. PubMed ID: 36301741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced Odds of Mpox-Associated Hospitalization Among Persons Who Received JYNNEOS Vaccine - California, May 2022-May 2023.
    Schildhauer S; Saadeh K; Vance J; Quint J; Salih T; Lo T; Keinde A; Chojolan E; Gotlieb E; Ramos M; Chapman E; Peters P; Watson J; Johnson KA; Tang EC; Jacobson K; Snyder RE
    MMWR Morb Mortal Wkly Rep; 2023 Sep; 72(36):992-996. PubMed ID: 37676838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mpox in people with past infection or a complete vaccination course: a global case series.
    Hazra A; Zucker J; Bell E; Flores J; Gordon L; Mitjà O; Suñer C; Lemaignen A; Jamard S; Nozza S; Nori AV; Pérez-Barragán E; Rodríguez-Aldama JC; Blanco JL; Delaugerre C; Turner D; Fuertes I; Leiro V; Walmsley SL; Orkin CM;
    Lancet Infect Dis; 2024 Jan; 24(1):57-64. PubMed ID: 37678309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levels of antibodies against the monkeypox virus compared by HIV status and historical smallpox vaccinations: a serological study.
    Li D; Wang H; Sun L; Feng J; Li W; Cheng L; Liao X; Zhang Y; Xu Z; Ge X; Zhou B; Zhao J; Ju B; Lu H; Zhang Z
    Emerg Microbes Infect; 2024 Dec; 13(1):2356153. PubMed ID: 38767199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JYNNEOS Vaccination Coverage Among Persons at Risk for Mpox - United States, May 22, 2022-January 31, 2023.
    Owens LE; Currie DW; Kramarow EA; Siddique S; Swanson M; Carter RJ; Kriss JL; Boersma PM; Lee FC; Spicknall I; Hurley E; Zlotorzynska M; Gundlapalli AV
    MMWR Morb Mortal Wkly Rep; 2023 Mar; 72(13):342-347. PubMed ID: 36995962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse Reactions After Intradermal Vaccination With JYNNEOS for Mpox in Korea.
    Lim SY; Jung YM; Kim Y; Kim G; Jeon J; Chin B; Kim MK
    J Korean Med Sci; 2024 Mar; 39(8):e100. PubMed ID: 38442725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monkeypox: Can we count on the current smallpox immunization?
    Zhang F; Chai Z; Wang X; Zhang Z; Yang Z; Liu W; Ren H; Jin Y; Yue J
    Virology; 2024 Apr; 592():109994. PubMed ID: 38277806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Demographic and Clinical Characteristics of Mpox in Persons Who Had Previously Received 1 Dose of JYNNEOS Vaccine and in Unvaccinated Persons - 29 U.S. Jurisdictions, May 22-September 3, 2022.
    Farrar JL; Lewis NM; Houck K; Canning M; Fothergill A; Payne AB; Cohen AL; Vance J; Brassil B; Youngkin E; Glenn B; Mangla A; Kupferman N; Saunders K; Meza C; Nims D; Soliva S; Blouse B; Henderson T; Banerjee E; White B; Birn R; Stadelman AM; Abrego M; McLafferty M; Eberhart MG; Pietrowski M; De León SM; Creegan E; Diedhiou A; Wiedeman C; Murray-Thompson J; McCarty E; Marcinkevage J; Kocharian A; Torrone EA; Ray LC; Payne DC;
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(5152):1610-1615. PubMed ID: 36580416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant proteins A29L, M1R, A35R, and B6R vaccination protects mice from mpox virus challenge.
    Tang D; Liu X; Lu J; Fan H; Xu X; Sun K; Wang R; Li C; Dan D; Du H; Wang Z; Li X; Yang X
    Front Immunol; 2023; 14():1203410. PubMed ID: 37435062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Status of Vaccine Development for Monkeypox Virus.
    Rastogi A; Kumar M
    Adv Exp Med Biol; 2024; 1451():289-300. PubMed ID: 38801585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.